New drug cocktail shows promise against tough pancreatic cancer
NCT ID NCT03138720
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of four drugs (paclitaxel protein bound, gemcitabine, cisplatin, and paricalcitol) given before surgery to people with pancreatic cancer that could or could not be removed. The goal was to see if the treatment could shrink tumors and improve surgical outcomes. 40 participants were enrolled, and researchers measured tumor markers and how many tumors could be completely removed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- A sound wave that could expose hidden pancreatic cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors
- Light-Activated therapy targets pancreatic tumors during surgery
- Engineered immune cells take aim at Mesothelin-Positive tumors